N-[4,5-dihydroxy-6-(hydroxymethyl)-2-propoxyoxan-3-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[4,5-dihydroxy-6-(hydroxymethyl)-2-propoxyoxan-3-yl]acetamide
• 化学式: C₁₁H₂₁NO₆
• 分子量: 263.29
• InChiKey: ZQKFRTNUONNUBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Suzhou Ribo Life Science Co., Ltd.

  公开号：EP3903830A1

  公开（公告）日：2021-11-03

  Provided are an siRNA for inhibiting the expression of the apolipoprotein C3 gene, and a pharmaceutical composition and a conjugate containing the siRNA. Each nucleotide in the siRNA is, respectively and independently, a modified or unmodified nucleotide; the siRNA contains a sense strand and an anti-sense strand; the sense strand includes nucleotide sequence I; nucleotide sequence I has the same length as the nucleotide sequence as shown in SEQ ID NO: 1, and not more than three nucleotides are different; the anti-sense strand contains nucleotide sequence II; and nucleotide sequence II has the same length as the nucleotide sequence as shown in SEQ ID NO: 2, and not more than three nucleotides are different. The siRNA provided by the present disclosure and the pharmaceutical composition and the conjugate thereof can effectively treat and/or prevent dyslipidemia.

  本发明提供了一种用于抑制脂蛋白 C3 基因表达的 siRNA，以及含有该 siRNA 的药物组合物和共轭物。siRNA 中的每个核苷酸分别独立地为修饰或未修饰的核苷酸；siRNA 包含有义链和无义链；有义链包括核苷酸序列 I；核苷酸序列 I 与 SEQ ID NO：1中所示的核苷酸序列具有相同的长度，不同的核苷酸不超过3个；反义链包含核苷酸序列II；核苷酸序列II与SEQ ID NO: 2中所示的核苷酸序列具有相同的长度，不同的核苷酸不超过3个。本公开提供的 siRNA 及其药物组合物和共轭物可有效治疗和/或预防血脂异常。